Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Bioventus Inc.NASDAQ: BVS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 67.9%

Gross margin was 67.9% in Q1 FY2026, up 2.1 pp from a year earlier. On a trailing-twelve-month basis it was 67.8%, up 0.6 pp year over year. Over 3 fiscal years it widened by 2.7 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
67.9%-0.2 pp QoQ
Last fiscal yearDec 2025
67.3%-0.4 pp YoY
LTMMar 2026
67.8%+0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.1 pp——
1 year-0.4 pp——
3 years+2.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
67.3%
Year-over-year change
-0.4pp

Gross Margin vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 gross margin of 67.8% is the 6th highest of the 9 companies compared; the peer median is 68.0%.
  • Its year-over-year change of +0.6 pp is the 3rd highest of 9, against a peer median of -0.6 pp.
  • Over three fiscal years its change of +2.7 pp compares with a peer median of -1.9 pp.
BVS Competitors Peer median
Gross Margin for BVS and competitors
Company Period LTM level YoY 3-year change
MDXGMiMedx Group, Inc.LTM Mar 202681.0% -0.8 pp+0.6 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 202670.4% -5.4 pp-1.1 pp
OFIXOrthofix Medical Inc.LTM Mar 202669.0% +1.9 pp-6.1 pp
SNNSmith & Nephew plcFY202568.3% -2.0 pp-2.7 pp
TELATELA Bio, Inc.LTM Jun 202667.8% +0.5 pp+2.4 pp
BVSBioventus Inc.LTM Mar 202667.8% +0.6 pp+2.7 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 202662.3% +4.2 pp+7.5 pp
ANIKAnika Therapeutics, Inc.LTM Mar 202658.6% -4.1 pp-7.8 pp
IARTIntegra LifeSciences Holdings CorporationLTM Mar 202653.2% -0.3 pp-10.6 pp
Peer median (excluding BVS) 68.0%-0.6 pp-1.9 pp

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue430.9M512.12M512.35M573.28M568.09M
Cost of Revenue128.19M181.04M184.15M185.05M185.66M
Gross Profit302.71M331.08M328.19M388.23M382.43M
Gross Margin70.3%64.6%64.1%67.7%67.3%
Research & Development19.04M23.85M13.45M13.64M12.11M
Selling, General & Admin254.25M332.13M303.88M327.09M311.77M
Operating Expenses290.65M498.31M409.92M400.21M323.88M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
EBITDA45.48M(121.61M)(23.07M)39.22M99.21M
EBITDA Margin10.6%-23.7%-4.5%6.8%17.5%
Operating Income12.06M(167.23M)(81.73M)(11.98M)58.55M
Operating Margin2.8%-32.7%-16.0%-2.1%10.3%
Interest Income00000
Interest Expense1.11M12.02M40.68M38.79M26.49M
Other Income / Expenses(2.57M)(21.79M)(39.39M)(37.15M)(32.84M)
Income Before Tax9.49M(189.03M)(121.11M)(49.13M)25.71M
Pre-Tax Margin2.2%-36.9%-23.6%-8.6%4.5%
Income Tax Expense(1.97M)(44.37M)85K(5.29M)(1.57M)
Net Income19.38M(158.7M)(156.23M)(33.54M)22.73M
Net Margin4.5%-31.0%-30.5%-5.9%4.0%
EPS (Basic)(0.15)(2.59)(2.49)(0.52)0.34
EPS (Diluted)(0.15)(2.59)(2.49)(0.52)0.33
Weighted Avg Shares45.47M61.39M62.65M65.36M66.62M
Weighted Avg Shares (Diluted)45.47M61.39M62.65M65.36M68.91M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.